THE two major clinical
shortcomings of morphine use in
pain therapy, namely potentially
fatal respiratory depression
and addiction, appear to have
been overcome in a tailor-made
substitute product, the result of
novel research out of universities in
the US and Germany and published
in the journal Nature.
Dubbed PZM21, this structurally
designed product has proven
to be at least equally successful
as an analgesic but does not
cause respiratory depression nor
“reinforcing activity” on dopamine
reward centres at therapeutic levels
in mice, authors state.
Extensive further research will be
required before the drug can be
tested on humans, the paper said.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Aug 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.